Deal follows two-year exclusive supply arrangement.

Sartorius Stedim Biotech (SSB) is taking over Wave Biotech AG after being an exclusive supplier of its single-use product portfolio for over two years. Wave products are expected to bring in €10 million in revenues for the current financial year.

Even though this will be a small part of SSB’s revenue stream, Petra Kirchhoff, vp of group corporate communications, stressed the acquisition is more about the growth potential of single-use bioreactors (SUBs). Besides being able to supply SUBs as well as the conventional stainless steel reactors, from an R&D perspective, SSB can now work on hybrid solutions, she adds.

Sartorius Stedim Biotech exclusively marketed Wave’s entire product range that covers various types of disposable bioreactors and equipment for biopharmaceutical research and manufacture. The companies also have joint research projects. This agreement, however, was set to expire in 2010.

“We are acquiring a company with a very strong track record in innovation and with competencies in fermentation that are outstandingly complementary with our own breadth of expertise in this area,” remarks Joachim Kreuzburg, CEO of Sartorius Stedim Biotech, about the acquisition. “In making this move, we are reinforcing our position in the fast-growing segment of single-use systems for cell cultivation over the long run.”

Previous articleAllergan to Use Polyphor’s Protein Epitope Mimetics Technology in Ophthalmology for $7M
Next articleChemical Process to Increase Potential of Stem Cells Reported